Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001819790-25-000023
Filing Date
2025-03-07
Accepted
2025-03-07 16:18:13
Documents
1
Period of Report
2025-03-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1741382286.html 4  
1 FORM 4 wk-form4_1741382286.xml 4 6328
  Complete submission text file 0001819790-25-000023.txt   7755
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Wahl Bryan (Reporting) CIK: 0001841401 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 25720324